Hydrochlorthiazide

Hydrochlorthiazide

SCHEMBL4937016

O=C(CBr)c1ccc([N+](=O)[O-])cc1.c1cscn1

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.68
MAPT P10636 7/20 0.47
ALDH1A1 P00352 4/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 2/20 0.47
CYP19A1 P11511 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
CES1 P23141 1/20 0.42
NOS1 P29475 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
MPI P34949 1/20 0.41
GAA P10253 2/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL73490 0.82 GSK3B (1.00) GSK3BALDH1A1CES1TDP1CA1
Hydrochlorthiazide SCHEMBL4936607 0.80 GSK3B (0.61) GSK3BMAPTALDH1A1MEN1KMT2A
Methylsulfanylmethane SCHEMBL28782214 0.78 GSK3B (0.89) GSK3BMAPTALDH1A1MEN1KMT2A
SCHEMBL7369237 0.78 GSK3B (0.89) GSK3BALDH1A1CES1TDP1CA1
Paranitrobenzyl Alcohol SCHEMBL28146144 0.77 POLB (0.49) MAPTALDH1A1KMT2ACYP19A1L3MBTL1
Hydrochlorthiazide SCHEMBL27468616 0.75 CYP1A2 (0.46) GSK3BMAPTALDH1A1MEN1KMT2A
4-Nitroaniline SCHEMBL27694794 0.75 ALDH1A1 (0.60) MAPTALDH1A1MEN1KMT2AKDM4E
Nitrobenzene SCHEMBL27321664 0.75 ALDH1A1 (0.57) MAPTALDH1A1MEN1KMT2ACYP19A1
SCHEMBL40529 0.74 GSK3B (0.81) GSK3BMAPTMEN1KMT2AKDM4E
Acetonitrile SCHEMBL27927677 0.74 GSK3B (0.81) GSK3BMAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293931-A1 Methods and compositions for the removal of nucleic acid amplification inhibitors LOS ALAMOS NATIONAL SECURITY, LLC 2008-11-27 US disclosed
US-20070065841-A1 Methods and compositions for the removal of nucleic acid amplification inhibitors ENERGY, U.S. DEPARTMENT OF 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293931-A1 Methods and compositions for the removal of nucleic acid amplification inhibitors POLRMT, FBL, POLL GSK3B 3452/4885MAPT 2739/4885ALDH1A1 2004/4885
US-20070065841-A1 Methods and compositions for the removal of nucleic acid amplification inhibitors POLRMT, FBL, POLL GSK3B 3452/4885MAPT 2739/4885ALDH1A1 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.